比阿培南治疗重度及以上慢性阻塞性肺疾病急性加重期的疗效观察  

Effect of biapenem in the treatment of severe and very severe acute exacerbation of chronic obstructive pulmonary disease

作　　者：宋应健[1] 孟自力[1] 洪永青[1] 王立新[1] 高新怀[1] 

机构地区：[1]南京医科大学附属淮安第一医院呼吸科,江苏淮安223300

出　　处：《中国医院药学杂志》2011年第24期2035-2038,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:评价比阿培南经验性治疗重度及以上(Ⅲ、Ⅳ级)慢性阻塞性肺疾病急性加重期的疗效和安全性。方法:80例慢性阻塞性肺疾病急性加重期(AECOPD)患者随机分为比阿培南治疗组和头孢他啶对照组,疗程均为7～10d。结果:治疗组临床疗效和细菌清除率(72.6%,88.2%)均优于对照组(60.0%,68.6%),肺功能改善优于对照组,两组药物不良反应发生率均较低。结论:比阿培南经验性治疗重度及以上AECOPD有效且安全。OBJECTIVE To evaluate the clinical efficacy and safety of biapenem in the treatment of severe and very severe acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. METHODS 80 patients with AECOPD were randomly divided into two groups, the trial and the control groups. Biapenem or ceftazidime were administered by intravenous infusion for 7 - 10 days. RESULTS The effective rates for trial group were higher than the control group （72.6% ,60. 0%）. The bacterial eradication rates for trial group were also higher than the control group（88. 2% ,68. 6%）. The lung function of trial group was significantly improved compared to the control group. The incidence of drug adverse reaction were all low. CONCLUSION Biapenem is both effective and safe drug for severe and very severe AECOPD.

关 键 词：比阿培南 头孢他啶 慢性阻塞性肺疾病 临床疗效 细菌清除率 

分 类 号：R285.5[医药卫生—中药学]